Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy

Objectives Humoral vaccine responses to SARS-CoV-2 vaccines are impaired and short lasting in patients with immune-mediated inflammatory diseases (IMID) following two vaccine doses. To protect these vulnerable patients against severe COVID-19 disease, a three-dose primary vaccination strategy has be...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	RMD Open
المؤلفون الرئيسيون:	Jorgen Jahnsen, Ingrid Egeland Christensen, Joe Sexton, Silje Watterdal Syversen, Guro Løvik Goll, Ingrid Jyssum, Trung T Tran, Kristin Hammersbøen Bjørlykke, Siri Mjaaland, David J Warren, Adity Chopra, Grete Birkeland Kro, Ludvig A Munthe, Gunnveig Grødeland, Kristin Kaasen Jørgensen
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	BMJ Publishing Group 2022-11-01
الوصول للمادة أونلاين:	https://rmdopen.bmj.com/content/8/2/e002417.full